Joseph Leach is moving into the CMO slot at Prime.
Prime Therapeutics LLC has named Joseph Leach, MD, as senior vice president and chief medical officer.
Leach brings over 20 years of experience to the Minnesota PBM as a clinician, researcher and health care leader to his role. He will lead the expansion of Prime’s specialty management capabilities and help shape the company’s total drug management strategy, according to a company press release.
“I couldn’t be more pleased to welcome Dr. Leach to Prime,” Prime’s President CEO, Ken Paulus, was quoted as saying in the press release. “Dr. Leach’s depth of experience in oncology therapy coupled with his devotion to patient-focused care will offer superb value to our clients and their members.”
Prime, which is headquartered in Eagan, Minnesota, a suburb of the Twin Cities, is owned by 18 Blue Cross and Blue Shield plans. In December, Prime and Express Scripts announced the formation of a collaboration. Express is now owned by Cigna.
Leach has held numerous leadership roles including medical director of Virginia Piper Cancer Institute in Minneapolis, past president of the Minnesota Society of Clinical Oncology and principal investigator for the Metro-Minnesota Community Oncology Research Consortium. He has also held national leadership positions in research including committee chair for the Eastern Cooperative Oncology Group and membership in the National Cancer Institute’s Thoracic Malignancy Steering Committee, says the press release from Prime,.
Leach graduated from St. Olaf College with a BA in biology and earned his MD at the University of Minnesota. He completed training in internal medicine and medical oncology at the University of Oklahoma in Oklahoma City and is a board-certified medical oncologist.
Muthiah “Muthu” Vaduganathan Discusses the Role of SGLT2 Inhibitors in Heart Failure Treatment
March 27th 2024Editors of Managed Healthcare Executive spoke with Muthiah “Muthu” Vaduganathan MD, MPH, consultant cardiologist at Brigham and Women's Hospital and a member of faculty at Harvard Medical School, about the evolving treatment landscape for heart failure, emphasizing the use of SGLT2 inhibitors alongside other foundational therapies.
Read More
In this second part of a two-part podcast episode, Managed Healthcare Executive's Managing Editor Peter Wehrwein spoke with CeCi Connolly and Margaret "Meg" Murray about Medicare Advantage utilization and challenges, highlighting proposed CMS payment cuts and prior authorization issues.
Listen
With aging populations, osteoporosis rates are set to increase, and researchers are looking for the next innovative drug to help prevent or manage the bone disease as there is currently no drug that completely does so effectively, according to a recent study published in Advanced Science.
Read More
In this first part of a two-part podcast episode, Managed Healthcare Executive's Managing Editor Peter Wehrwein kicks off our new podcast series "DC Roundtable," with guests Margaret "Meg" Murray, CEO of the Association of Community Affiliated Plans, and member of MHE's Editorial Advisory Board, and CeCi Connolly, president and CEO of the Alliance of Community Health Plans, for a discussion on healthcare policy issues.
Listen
2024 Emerging Leaders in Healthcare — Submit For a Chance to Be Featured in MHE's August Issue
March 26th 2024MHE Editors are seeking diverse healthcare professionals from different backgrounds and healthcare sectors, with individual interests. Eligible candidates are early or mid-career leaders with less than 10 years of experience. Award winners will enjoy complimentary passes to the PBMI Annual National Meeting in Orlando, Florida, from Sept. 4-6. Additional perks include a feature in our August issue, a subscription to MHE and more!
Read More